Publication date: May 31, 2025
COVID-19 is associated with a broad spectrum of bacterial and fungal superinfections. We present a case of mucormycosis developing during post-COVID-19 therapeutic management. A 63-year-old diabetic female presented with COVID-19 and received combination therapy per institutional protocol, including dexamethasone, remdesivir, and ivermectin. Seven days post-discharge, the patient was readmitted with dyspnea and lethargy. On day 3 of readmission, the patient reported unilateral facial and orbital pain. Subsequent histopathological and mycological examination confirmed mucormycosis. Despite surgical debridement and treatment with amphotericin B (3 mg/kg/day), the patient succumbed to the infection. Based on ITS rDNA sequencing, the fungus was identified as Rhizopus arrhizus. Antifungal susceptibility testing was performed according to the CLSI M38-A2 guideline, yielding minimum inhibitory concentration (MIC) values of 0. 016 ug/mL for amphotericin B, 0. 031 ug/mL for posaconazole, 0. 25 ug/mL for isavuconazole, 1 ug/mL for itraconazole, and 8 ug/mL for voriconazole. Early diagnosis, prompt antifungal therapy, and appropriate surgical intervention are critical for improving mucormycosis outcomes, especially in COVID-19 patients.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | mucormycosis |
| disease | MESH | diabetes mellitus |
| disease | MESH | superinfections |
| drug | DRUGBANK | Dexamethasone |
| drug | DRUGBANK | Ivermectin |
| disease | MESH | dyspnea |
| drug | DRUGBANK | Amphotericin B |
| disease | MESH | infection |
| disease | IDO | susceptibility |
| drug | DRUGBANK | Methyl isocyanate |
| drug | DRUGBANK | Posaconazole |
| drug | DRUGBANK | Isavuconazole |
| drug | DRUGBANK | Itraconazole |
| drug | DRUGBANK | Voriconazole |
| disease | IDO | intervention |
| disease | MESH | Diabetes Complications |
| disease | MESH | Fatal Outcome |
| disease | MESH | Orbital Diseases |
| disease | MESH | zygomycosis |